Vitamin D Testing Market Size Worth $1.1 Billion By 2025

The global vitamin D testing market size is expected to reach USD 1.1 billion by 2025, at a CAGR of 9.4% according to a new report by Grand View Research, Inc. Global increase in geriatric population as well as cases of chronic illnesses is likely to drive the market during the forecast period.

Furthermore, increase in investment for development and commercialization of various accurate, innovative, and easy-to-use tests by various market players and governments is likely to drive the market growth. For instance, in January 2017, Future Diagnostics and DIA source received a grant of EUR 1.4 million from the European Commission to develop a unique CE-marked assay that can measure the level of free vitamin D (25OHD) in the body. In addition, this assay will assist in early recovery of patients suffering from vitamin D deficiency by providing optimized treatment, offering an opportunity to save treatment costs.

Vitamin D assay measures the level of vitamin D in two forms. Hence, the market has been divided by two major types of tests, namely 25-Hydroxy Vitamin D test and 1, 25-Dihydroxy vitamin test.

The 5-hydroxy vitamin D tests or assay segment dominated in 2016 due to its greater ability to identify bone malformations, softness, weakness, and fractures in adults. Its domination is likely to continue in the forecast period as well.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/vitamin-d-testing-market

Further Key Findings From the Report Suggest:

Rising incidence of chronic illnesses and growing geriatric population are expected to propel the growth of the vitamin D testing market with a CAGR of 9.4% from 2017 to 2025
5-hydroxy vitamin D test segment accounted for the largest share and is anticipated to witness strong growth during the forecast period. This can be attributed to the availability of several commercial products, ongoing research in the field, and the ability to accurately detect bone malformations.
Geographically, North America held the largest share in 2016. It is expected to maintain its dominance during the forecast period due to higher awareness about screening, higher healthcare expenditure as compared to other developing countries, and local presence of market players.
The industry in Asia Pacific is projected to witness substantial growth over the next decade owing to growing investments by several market players in the region, growing healthcare expenditure, and recent commercialization of tests in major markets, such as Japan and China
Some of the key players are Abbott Laboratories; F. Hoffmann-La Roche Ltd.; Hologic, Inc.; Siemens Corporation; Danaher Corporation; Quest Diagnostics, Inc.; bioMérieux SA; and DiaSorin S.p.A.

Antinuclear Antibody Test Market Size Worth $2.36 Billion By 2025

The global antinuclear antibody test market size is expected to reach USD 2.36 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 12.5% over the forecast period. Rising adoption of ANA test coupled with government initiatives to treat autoimmune disorders is likely to drive the market. Furthermore, rising incidence of autoimmune disorders is projected to fuel the growth.

Antinuclear Antibody (ANA) testing is an important tool to diagnose and manage autoimmune diseases such as Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis. According to the Lupus Foundation of America, at least 5 million people globally and around 1.5 million people in U.S. have a form of lupus. Around 16,000 new cases are registered every year. The disease mostly affects women of childbearing age. SLE accounts for almost 70% of all cases of lupus. The high prevalence of autoimmune disorders is one of the factors driving the market.

Extension of ANA from a test for SLE to a test for any autoimmune diseases has boosted the usage of antinuclear antibody testing. An increase in ANA demand may also be due to the factors such as expanded role of primary care physicians in healthcare delivery systems. In addition, rising R&D activities and government initiatives regarding early diagnosis of autoimmune disorders have triggered the demand for ANA tests.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/antinuclear-antibody-ana-test-market

Further key findings from the study suggest:

Reagents and assay kits was the largest segment in 2017. It is likely to witness fastest growth over the forecast period due to wide usage and rise in a number of reagent rental agreements
Immunofluorescence assay led the market in terms of market share in 2017 owing to superior sensitivity compared to other available techniques
ELISA is expected to be the fastest growing segment over the forecast period. Increasing adoption of these tests is attributed to easy automation and handling without high level of operator skill
Rheumatoid arthritis segment is projected to hold largest market share, mainly due to high prevalence of the disease
North America was the largest region in terms of revenue in 2017, followed by Europe. Both are the most well-established regions in terms of the adoption of ANA testing and make up most of the existing market
Asia Pacific is likely to be the fastest growing region over the forecast period due to unmet clinical needs and need for better diagnosis. Rising government initiatives and clinical research activities for advanced diagnostics are expected to further fuel growth
Key players operating in the antinuclear antibody test market are Thermo Fisher Scientific Inc.; Alere Inc.; Bio-Rad Laboratories; Trinity Biotech PLC; Zeus Scientific, Inc.; Inova Diagnostics; Immuno Concepts; Erba Diagnostics, Inc.; Euroimmun AG; and Antibodies Inc.
Key companies are adopting R&D, geographic expansion, and collaborations to gain market share.

Heart Attack Diagnostics Market Worth $15.4 Billion By 2024

The heart attack diagnostics market is expected to reach USD 15.4 billion by 2024, according to a new report by Grand View Research, Inc. The heart attack diagnostics market is anticipated to witness a lucrative growth during the forecast period from2016 to 2024. From 2001 to 2011, age-standardized, heart attack incidence rates have significantly decreased worldwide. However, the overall risk factors and the disease burden remains large, thereby rendering the heart attack diagnostic sectors a profitable growth prospect. This growth is attributed to a majority of factors, such as high prevalence of coronary heart diseases, increased tobacco smoking, and obesity, enhanced adoption of unhealthy diet is resulting in a high cholesterol incidence in individuals, particularly in the rising geriatric population. However, the low Medicare reimbursement provided for the mobile cardiac outpatient telemetry electrocardiogram (ECG) and the progressively declining heart attack incidence rates are expected to hamper the market growth.

The heart attack diagnostics market has been classified by product into electrocardiogram, which measures the electrical activity of the heart; echocardiogram, a form of ultrasound test that provides images of the heart; blood tests that measure the expression of certain proteins in excess, such as troponin levels, and cardiac enzymes; and other diagnostic products. The ECG segment is expected to witness a significant growth rate in developing countries, owing to the technological advances coupled with increasing applications of ECG. Although, the increasing demand for cost effective, rapid blood tests such as troponin and Creatine Kinase MB Isoenzyme (CK-MB) is likely to acquire major market share in the near future. The key countries landscape included in the report are U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa, and Middle East. The Asia Pacific region is anticipated to be the fastest growing region during the forecast period. On the other hand, North America is estimated to dominate the global heart attack diagnostics market.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/heart-attack-diagnostics-market

Further key findings from the study suggest:

North America is estimated to dominate the global heart attack diagnostics market. The increasing awareness about heart attacks, its causative and risk factors, and enhanced uptake and acceptance of technologically advanced diagnostics is expected to contribute to the market growth.
The Asia Pacific region is expected to be the fastest growing region during the forecast period. to The reason being the considerably large burden of heart diseases in certain developing regions, such as in India, where 2.4 million people die annually due to heart diseases. As a result of the soaring incidences of heart diseases, an urgent requirement to undertake awareness measures and incorporate advanced diagnostics is expected to fuel the market growth.
The troponin blood test type is the largest grossing segment and is expected to capture the largest share in 2015, especially in developing countries including Brazil, China, and India. Its applications as a cardiac monitoring device and its indispensable use as a heart attack diagnostic tool will be a contributing factor supporting the market growth. The industry comprises of several local as well as global players. Some of the major players of this industry include Siemens Healthcare GmbH, Schiller AG, GE Healthcare, and Hitachi Medical Systems.

Transcriptomics Technologies Market Worth $6.9 Billion By 2022

The global transcriptomics technologies market is expected to reach USD 6.9 billion by 2022, according to a new report by Grand View Research Inc. The increasing demand for genetic identification and growing investment in R&D innovation along with the technological advancements across the product portfolio are the vital driving forces of this market. The increasing R&D investments are expected to highly influence biotechnological research and develop commercialization over the forecast period. The rising investment is further anticipated to ensure positive growth and enhance business opportunities for pharmaceutical and biotechnological companies.

Furthermore, the rising demand for efficient diagnostic methods drives the need for personalized medicines. Transcriptomics tools and the offered services identify potential drug targets, which are effective methods for diagnostic methodologies. The shifting preference of pharmaceutical companies towards therapeutics results in rising demand for disease-specific biomarker identification. This change ensures a potential opportunity in the commercialization of transcriptome research results. The escalating demand for efficient diagnostics and treatment measures in the areas of oncology, HIV, Alzheimer’s disease, etc., also contributes significantly towards transcriptomics technologies market growth.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/transcriptomics-technologies-market

Further key findings from the report suggest:

Polymerase Chain Reaction (PCR) based transcriptomics technologies market is expected to account for over 40% market share by 2022 owing to its ability to enable amplification even from very small amounts of genetic material samples
Next-generation Sequencing based transcriptomics technologies market is expected to grow at a lucrative CAGR of over 17.0% over the forecast period owing to increased outsourcing of sequencing technologies, upgrading of technology enabling the analysis of cellular transcriptome from various dimensions, and wide application areas of NGS
North America dominates the transcriptomics technologies market in terms of revenue owing to the increasing R&D activities by the biotechnology and pharmaceutical companies
North America and Asia Pacific are expected to witness the fastest growth of over 15.0% during the forecast period. The growth is due to the presence of untapped opportunities, rising expenditure levels, and the introduction of favorable government initiatives.
Key players of transcriptomics technologies market include Agilent Technologies, Affymetrix, Thermo Fisher Scientific, Illumina, Life Technologies, and F. Hoffmann-La Roche
Market participants are constantly engaged in strategic collaborations such as mergers and acquisitions along with technological advancements in an attempt to improve presence and ensure sustainability
For instance, in May 2015, Agilent Technologies announced the acquisition of Cartagenia that provides services and software for clinical genetic analysis. Their products are supplied to pathology laboratories and clinical research institutes. The acquisition is expected to provide higher integration and support customer satisfaction.

HIV Diagnostics Market Is Expected To Reach USD 4.48 Billion In 2022

Global HIV Diagnostics Market is expected to reach USD 4.48 billion by 2022, growing at an estimated CAGR of 9.5% from 2015 to 2022, according to a new study by Grand View Research, Inc. Key factors accounting for the growth of this market include the growing need in for the development of more sensitive HIV diagnostic point of care tests which can be easily implemented at the location of patient care in resource limited settings. Technological development of tests which is expected to introduce a number of novel rapid, point-of-care tests throughout the forecast period is a primary factor expected to fuel the growth of the HIV diagnostics market. Furthermore, government programs and campaigns initiated against HIV, global healthcare efforts to reduce disease incidence, and the presence of high unmet demand in the Middle Eastern and Eastern regions of the market are some key factors expected to serve as lucrative future growth opportunities.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/hiv-diagnostics-market

Further key findings from the study suggest:

Antibody HIV diagnostic tests accounted for the largest share of the market in 2014. This large share can be accounted for by the high market usage and penetration rates of these tests which include, ELISA, home access dried blood spot, western blot testing IFA and RIPA. These tests are highly sensitive and accurate and thus are most commonly used for screening and confirmation of HIV-1 & HIV-2.
Viral Load testing and CD4 testing also accounted for a considerable share of the market in 2014. There is a prevalent in the market for the development of these tests which will make them more sensitive, rapid in nature and portable to the point of care to enhance their market usability and accessibility in resource limited HIV affected regions.
It is expected that during the forecast period a number of novel point of care HIV diagnostic products will be commercialized which are currently under clinical development and in product pipelines of key market players. This increase in the range of products s expected to fuel the growth of this market over the forecast period.
North America was observed to account for the largest share of the market in 2014, which can be attributed to the presence of a strong healthcare R&D scenario in which the presence of government funding and ongoing corporate efforts to enhance product portfolio are anticipated to accelerate the timelines for new product development. Furthermore, the presence of favorable reimbursements policies for HIV and other infectious diseases is also a factor accounting for this region’s large share.
Asia Pacific is expected to grow at a relatively faster rate over the forecast period owing to, the presence of high levels of unmet market demand for HIV screening and testing. Moreover, collaborations among market participants from the western regions is another significant expected to boost the growth of Asia Pacific HIV diagnostics market during the forecast period.
Key players of the market include Janssen Diagnostics, Daktari Diagnostics, Cepheid, Hologic and Chembio Diagnostic Systmes Inc.